Pomaglumetad methionil Drug Asset Due Diligence Report 2026

This Pomaglumetad methionil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Pomaglumetad methionil can convert its Small molecule drug profile and mGluR2 x mGluR3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pomaglumetad methionil (query alias: Pomaglumetad methionil)
Modality / target	Small molecule drug; mGluR2 x mGluR3; mGluR2 agonists, mGluR3 agonists
Highest global status	Phase 2
Originator	Denovo Biopharma LLC
Active developers	Denovo Biopharma Co., Ltd.

The MCP disease footprint includes Schizophrenia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20192086	Phase 1	Completed	16	Primary endpoint not disclosed in English source
NCT03321617	Phase 1	Completed	16	Primary endpoint not disclosed in English source
NCT03106571	Phase 1	Terminated	19	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia

Phase 1; n=86; evaluation: Not stated in English source. Reported fields: 0.5 hours(LS Mean) = -7.1 ms (90%CI, -8.5 to -5.6); 0.5 hours(LS Mean) = -6.66 ms (90%CI, -8.21 to -5.11)

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia

Phase 3; n=567; evaluation: Not stated in English source. Reported fields: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score(LS Mean) = -4.8 Unit ; Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score(LS Mean) = -5.0 Unit

A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023

Phase 3; n=678; evaluation: Not stated in English source. Reported fields: Change From Baseline to 24 Weeks in Body Weight(LS Mean) = -2.8 kg ; Change From Baseline to 24 Weeks in Body Weight(LS Mean) = 0.4 kg

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pomaglumetad methionil addresses Schizophrenia. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2014-09-16	Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Pharmacotherapies for improving treatment adherence after discontinuation of incretin-based therapies”. The milestone feed surfaced a patent-application signal described as “Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use”. The milestone feed surfaced a patent-application signal described as “Method for treating schizophrenia and related diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO